Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 17/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR2B | P41595 | 4/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056205 | 0.88 | HTR6 (0.48) | HRH2HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL5748447 | 0.84 | HRH2 (0.43) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL13768719 | 0.84 | HRH2 (0.58) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL4055511 | 0.84 | HRH2 (0.53) | HRH2HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL8316249 | 0.83 | HTR6 (0.53) | HTR2CHTR6 | |
| SCHEMBL7136158 | 0.82 | HRH2 (0.49) | HRH2HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL4061658 | 0.81 | HTR2A (0.46) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL4060778 | 0.81 | HTR2A (0.43) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL4055298 | 0.80 | HRH2 (0.66) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6780310 | 0.78 | HRH2 (0.72) | HRH2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | claimed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | claimed |
| JP-2003501424-A | — | — | 2003-01-14 | — | — | JP | claimed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | claimed |
| EP-1183251-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2002-03-06 | — | — | EP | claimed |
| WO-2000075130-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-12-14 | — | — | WO | claimed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-7560471-B2 | 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage | LABORATORIOS ALMIRALL S.A. (ES) | 2009-07-14 | — | — | US | disclosed |
| US-20060094879-A1 | New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| EP-1513826-B1 | NEW INDOLYLPIPERIDINE DERIVATIVES AS POTENT ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-01-25 | — | — | EP | disclosed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
| EP-1183251-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075130-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HRH2 1/4885HTR2A 27/4885HTR2C 32/4885 |
| US-20060094879-A1 | New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents | HRH2, HRH4, HRH1 | HRH2 1/4885HTR2A 18/4885HTR2C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.